# A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

> **NCT00266552** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 118 (actual)

## Conditions studied

- Conduct Disorder
- Disruptive Behavior Disorder
- Oppositional Defiant Disorder

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00266552
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1998-10
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00266552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00266552, "A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00266552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*